Contact
searchSearch
HMP Global
Login

Support Resources

News
Patients Often Favor Receiving Information About Cancer Therapy From the Oncologist
02/14/2023
Yvette C. Terrie, BS Pharm, RPh
According to findings from a patient-completed questionnaire published in the Journal of Cancer Education, among oncology patients, many favored receiving pertinent information directly from the oncologist regarding various facets of...
According to findings from a patient-completed questionnaire published in the Journal of Cancer Education, among oncology patients, many favored receiving pertinent information directly from the oncologist regarding various facets of...
According to findings from a...
02/14/2023
Journal of Clinical Pathways
Research Reports
Post–COVID-19 Syndrome Clinical Pathway for the US Veterans Health Administration
02/06/2023
Allison M. Gustavson, DPT, PhD; Johnson Vachachira, NP; Claudia L. Campos, MD; Jacob B. Lindheimer, PhD; Kristina Crothers, MD; Omar Awan, MD; Carrie B. May, PsyD; Cristina Nguyen, BS; Courtney Sedillo, MSN, FNP-C; Francis J. Miller, Jr., MD
Lindheimer et al summarize the stepwise diagnostic approach for patients presenting with PCS dyspnea and/or cough in primary care and highlight teleconsultation and telerehabilitation as opportunities to reach those in rural areas or with...
Lindheimer et al summarize the stepwise diagnostic approach for patients presenting with PCS dyspnea and/or cough in primary care and highlight teleconsultation and telerehabilitation as opportunities to reach those in rural areas or with...
Lindheimer et al summarize the...
02/06/2023
Journal of Clinical Pathways
Trending From ACCC
Improving the Care of Patients With Advanced Nonmelanoma Skin Cancers
02/06/2023
In 2022, the Association of Community Cancer Centers (ACCC) developed the Advanced Non-Melanoma Skin Cancers Visiting Experts Program to educate multidisciplinary providers through interactive, virtual discussions on effective practices for...
In 2022, the Association of Community Cancer Centers (ACCC) developed the Advanced Non-Melanoma Skin Cancers Visiting Experts Program to educate multidisciplinary providers through interactive, virtual discussions on effective practices for...
In 2022, the Association of...
02/06/2023
Journal of Clinical Pathways
Debra Patt, MD, MPH, MBA
Videos
Reducing Disparities Through the Implementation of Digital Health Solutions in the Community Oncology Practice Setting
08/12/2022
Debra Patt, MD, MPH, MBA, implemented digital health solutions across a large practice, aiming to better understand which patient populations use these tools over time and characterize engagement across populations to enhance clinical...
Debra Patt, MD, MPH, MBA, implemented digital health solutions across a large practice, aiming to better understand which patient populations use these tools over time and characterize engagement across populations to enhance clinical...
Debra Patt, MD, MPH, MBA,...
08/12/2022
Journal of Clinical Pathways
Research Reports
Quality Measure Concepts to Fill Gaps in Assessing Oral Oncolytic Adherence: A Multistakeholder Measurement Strategy
06/16/2022
Sandra Kurtin, PhD; Leigh Boehmer, PharmD; Michael Reff, RPh, MBA; Rachael Peroutky, MSPH; David Blaisdell, BA; Shelley Fuld Nasso, MPP; Katie Schultz, MSPH; Tom Valuck, MD, JD
A multistakeholder workgroup of oncology and quality measurement experts explored gaps in quality measures focused on oral oncolytic adherence and identified, prioritized, and refined measure concepts for further development.
A multistakeholder workgroup of oncology and quality measurement experts explored gaps in quality measures focused on oral oncolytic adherence and identified, prioritized, and refined measure concepts for further development.
A multistakeholder workgroup of...
06/16/2022
Journal of Clinical Pathways
Conference Coverage
Real-World Utilization and Comparative Effectiveness of Treatment Options for Cancer–Associated Venous Thromboembolism
06/04/2022
Janelle Bradley
In the real-world setting, patients with cancer–associated venous thromboembolism remain on anticoagulation for a short period of time and DOACs and warfarin may be associated with better compliance than low molecular weight heparin.
In the real-world setting, patients with cancer–associated venous thromboembolism remain on anticoagulation for a short period of time and DOACs and warfarin may be associated with better compliance than low molecular weight heparin.
In the real-world setting,...
06/04/2022
Journal of Clinical Pathways
News
Immune Checkpoint Inhibitors May Have Been Used Inappropriately in Half of Study Patients with Advanced Cancer Who Were Near the End of Life
05/18/2022
Ellen Kurek
Immune checkpoint inhibitors (ICIs) have been shown to extend progression-free survival and overall survival in patients with a variety of cancers, leading to increases in the systemic treatment of patients with advanced cancer who are near...
Immune checkpoint inhibitors (ICIs) have been shown to extend progression-free survival and overall survival in patients with a variety of cancers, leading to increases in the systemic treatment of patients with advanced cancer who are near...
Immune checkpoint inhibitors...
05/18/2022
Journal of Clinical Pathways
Rachael Peroutky, MSPH
Quality Outlook
Nurses are Burned Out. Can Quality Measures Help?
04/11/2022
Sarena Ho, MSPH; Sara Khan Shirsekar; Katie Schultz, MSPH; Rachael Peroutky, MSPH; Tom Valuck, MD, JD; Elizabeth Donckels, MSPH
This blog addresses "nurse burnout," the occupational phenomena that many nurses face, and suggests that quality measurement strategies for nurse burnout may be most effective in the hospital setting since evidence tying burnout to patient...
This blog addresses "nurse burnout," the occupational phenomena that many nurses face, and suggests that quality measurement strategies for nurse burnout may be most effective in the hospital setting since evidence tying burnout to patient...
This blog addresses "nurse...
04/11/2022
Journal of Clinical Pathways
Research Reports
Factors Associated With Poor Outcomes in Patients who Receive Cancer Directed Therapy at the End of Life
02/15/2022
Megan Wall, MS; Ila M. Saunders, PharmD, BCOP; Janine Martino, PharmD, BCOP, APh; Alison Wall, MS; Shanna Block, PharmD, BCOP; Rabia S. Atayee, PharmD, BCPS; Katherine Medley, PharmD; Yasmine Anouty, PharmD; Carolyn Mulroney, MD
Yasmine Anouty, PharmD, and colleagues discern factors that may be associated with poor outcomes in adult patients who received intravenous cancer-directed therapy in the last 30 days of life.
Yasmine Anouty, PharmD, and colleagues discern factors that may be associated with poor outcomes in adult patients who received intravenous cancer-directed therapy in the last 30 days of life.
Yasmine Anouty, PharmD, and...
02/15/2022
Journal of Clinical Pathways

Expert Insights

Debra Patt, MD, MPH, MBA
Videos
Reducing Disparities Through the Implementation of Digital Health Solutions in the Community Oncology Practice Setting
08/12/2022
Debra Patt, MD, MPH, MBA, implemented digital health solutions across a large practice, aiming to better understand which patient populations use these tools over time and characterize engagement across populations to enhance clinical...
Debra Patt, MD, MPH, MBA, implemented digital health solutions across a large practice, aiming to better understand which patient populations use these tools over time and characterize engagement across populations to enhance clinical...
Debra Patt, MD, MPH, MBA,...
08/12/2022
Journal of Clinical Pathways
Interview
Building Clinical Pathways With an Emphasis on Specific Community Needs
12/16/2020
Carla Baker, RN, discusses the Memphis Breast Cancer Consortium, including the organization's mission, structure, and approach to pathways design.
Carla Baker, RN, discusses the Memphis Breast Cancer Consortium, including the organization's mission, structure, and approach to pathways design.
Carla Baker, RN, discusses the...
12/16/2020
Journal of Clinical Pathways
Healthcare Economist
PCORI to Incorporate Cost But Not Cost-Effectiveness in its New Principles
10/09/2020
Jason Shafrin, PhD, highlights the Patient-Centered Outcomes Research Institute's (PCORI) Proposed “Principles” for the Consideration of the Full Range of Outcomes Data.
Jason Shafrin, PhD, highlights the Patient-Centered Outcomes Research Institute's (PCORI) Proposed “Principles” for the Consideration of the Full Range of Outcomes Data.
Jason Shafrin, PhD, highlights...
10/09/2020
Journal of Clinical Pathways
Guest Blog
Achieving “Victory” Through Holistic Palliative Care
07/03/2019
Adil Akhtar, MD
Adil Akhtar, MD, offers the perspective that, if patients can learn to see their bodies as more important than their cancer, they will be more likely to agree to and continue palliative care.
Adil Akhtar, MD, offers the perspective that, if patients can learn to see their bodies as more important than their cancer, they will be more likely to agree to and continue palliative care.
Adil Akhtar, MD, offers the...
07/03/2019
Journal of Clinical Pathways
Guest Blog
Pharmacogenomics: Preemptive Testing Decisions Reach Across the Care Team
01/07/2019
Kandace Schuft, PharmD
Kandace Schuft, PharmD, discusses the challenges of implementing pharmacogenomics testing in actual practice and determining its place in the workflow of multiple care teams.
Kandace Schuft, PharmD, discusses the challenges of implementing pharmacogenomics testing in actual practice and determining its place in the workflow of multiple care teams.
Kandace Schuft, PharmD,...
01/07/2019
Journal of Clinical Pathways
Guest Blog
Why Palliative Care is More Than Just Care for the Dying
04/28/2018
Tim Holder, MD
Many physicians still mistakenly believe that hospice and palliative medicine are one and the same, according to Timothy W Holder, MD, medical director, supportive care and survivorship, Cancer Treatment Centers of America.
Many physicians still mistakenly believe that hospice and palliative medicine are one and the same, according to Timothy W Holder, MD, medical director, supportive care and survivorship, Cancer Treatment Centers of America.
Many physicians still mistakenly...
04/28/2018
Journal of Clinical Pathways
Deirdre Saulet, PhD
Blog
How AI, Data, and Real-World Evidence Are Transforming Oncology Clinical Pathways
07/14/2026
Deirdre Saulet, PhD
Clinical Pathways Congress 2026 will bring together oncology leaders to explore practical strategies for using technology to build smarter, more responsive clinical pathways that improve care delivery.
Clinical Pathways Congress 2026 will bring together oncology leaders to explore practical strategies for using technology to build smarter, more responsive clinical pathways that improve care delivery.
Clinical Pathways Congress 2026...
07/14/2026
Journal of Clinical Pathways
B-cell lymphoma
Videos
Dual-Targeting CAR T-Cell Therapy: Implications for Relapsed or Refractory Large B-Cell Lymphoma
07/06/2026
Paolo Strati, MD
  Key Clinical Summary Dual-targeting CAR T-cell therapy shows promise: Findings from the phase 2 ZUMA-14 trial suggest that combining axicabtagene ciloleucel (axi-cel) with rituximab may improve response durability by...
  Key Clinical Summary Dual-targeting CAR T-cell therapy shows promise: Findings from the phase 2 ZUMA-14 trial suggest that combining axicabtagene ciloleucel (axi-cel) with rituximab may improve response durability by...
  Key Clinical...
07/06/2026
Journal of Clinical Pathways
Non-small cell lung cancer, NSCLC
Videos
Evaluating First-Line TKIs in ALK-Positive NSCLC: Insights From a Large Real-World Analysis: Part 2
06/19/2026
Rahul Mudumba, PhD, MHS
Dr Rahul Mudumba discusses how emerging real-world evidence may help differentiate ALK-targeted therapies for non–small cell lung cancer (NSCLC), highlighting the promise of lorlatinib, the importance of patient-specific treatment decisions,...
Dr Rahul Mudumba discusses how emerging real-world evidence may help differentiate ALK-targeted therapies for non–small cell lung cancer (NSCLC), highlighting the promise of lorlatinib, the importance of patient-specific treatment decisions,...
Dr Rahul Mudumba discusses how...
06/19/2026
Journal of Clinical Pathways
NSCLC, non-small cell lung cancer
Videos
Evaluating First-Line TKIs in ALK-Positive NSCLC: Insights From a Large Real-World Analysis
06/18/2026
Rahul Mudumba, PhD, MHS
Rahul Mudumba, PhD, explains how real-world evidence is helping clarify first-line treatment selection among ALK-targeted therapies in ALK-positive non–small cell lung cancer (NSCLC).
Rahul Mudumba, PhD, explains how real-world evidence is helping clarify first-line treatment selection among ALK-targeted therapies in ALK-positive non–small cell lung cancer (NSCLC).
Rahul Mudumba, PhD, explains how...
06/18/2026
Journal of Clinical Pathways
Specialty Pharmacy, Clinical Pathways, Oncology
Videos
Building Better Oncology Pathways With Specialty Pharmacy Integration: Part 2
06/17/2026
Kishen Patel, PharmD
Kishen Patel, PharmD, explores how integrated specialty pharmacy services are helping health systems reduce acute care utilization, strengthen oncology pathways, and demonstrate the long-term value of pharmacist-led care.
Kishen Patel, PharmD, explores how integrated specialty pharmacy services are helping health systems reduce acute care utilization, strengthen oncology pathways, and demonstrate the long-term value of pharmacist-led care.
Kishen Patel, PharmD, explores...
06/17/2026
Journal of Clinical Pathways
Specialty Pharmacy, Clinical Pathways, Oncology
Videos
Building Better Oncology Pathways With Specialty Pharmacy Integration
06/17/2026
Kishen Patel, PharmD
In this interview, Kishen Patel, PharmD, discusses how pharmacist-led interventions and integrated specialty pharmacy services can improve adherence, address treatment barriers, and support better outcomes for patients receiving oral oncology...
In this interview, Kishen Patel, PharmD, discusses how pharmacist-led interventions and integrated specialty pharmacy services can improve adherence, address treatment barriers, and support better outcomes for patients receiving oral oncology...
In this interview, Kishen Patel,...
06/17/2026
Journal of Clinical Pathways
DLBCL, Diffuse Large B-Cell Lymphoma
Interview
Cardiopulmonary Comorbidities and CRS Risk After CAR T-Cell Therapy in DLBCL: Insights From Real-World Data
06/11/2026
Heidi Cho, MD
Real-world data suggest that common cardiac and pulmonary comorbidities may play an important role in cytokine release syndrome (CRS) risk in patients with diffuse large B-cell lymphoma (DLBCL).
Real-world data suggest that common cardiac and pulmonary comorbidities may play an important role in cytokine release syndrome (CRS) risk in patients with diffuse large B-cell lymphoma (DLBCL).
Real-world data suggest that...
06/11/2026
Journal of Clinical Pathways
DLBCL, Diffuse Large B-Cell Lymphoma
Videos
Real-World Survival Impact of CAR T Therapy in Advanced DLBCL: Findings From a SEER Database Analysis: Part 2
05/27/2026
Nishanth Thalambedu, MD
This discussion explores the ongoing barriers to CAR T access and the strategies needed to expand equitable treatment for patients with diffuse large B-cell lymphoma (DLBCL).
This discussion explores the ongoing barriers to CAR T access and the strategies needed to expand equitable treatment for patients with diffuse large B-cell lymphoma (DLBCL).
This discussion explores the...
05/27/2026
Journal of Clinical Pathways
Diffuse Large B-Cell Lymphoma, DLBCL
Videos
Real-World Survival Impact of CAR T Therapy in Advanced DLBCL: Findings From a SEER Database Analysis
05/26/2026
Nishanth Thalambedu, MD
A SEER database analysis demonstrates significant improvements in overall survival for patients with diffuse large B-cell lymphoma (DLBCL) following the introduction of CAR T therapy.
A SEER database analysis demonstrates significant improvements in overall survival for patients with diffuse large B-cell lymphoma (DLBCL) following the introduction of CAR T therapy.
A SEER database analysis...
05/26/2026
Journal of Clinical Pathways
Mark A. Socinski, MD
Interview
The Ongoing Challenges Facing TIGIT Inhibitors in Lung Cancer: Part II
05/26/2026
Mark A. Socinski, MD
In the second installment of this interview, a guest expert reflects on the broader implications of the negative SKYSCRAPER-06 results for the future of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory...
In the second installment of this interview, a guest expert reflects on the broader implications of the negative SKYSCRAPER-06 results for the future of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory...
In the second installment of...
05/26/2026
Journal of Clinical Pathways

Newsfeed

News
Patients Often Favor Receiving Information About Cancer Therapy From the Oncologist
02/14/2023
Yvette C. Terrie, BS Pharm, RPh
According to findings from a patient-completed questionnaire published in the Journal of Cancer Education, among oncology patients, many favored receiving pertinent information directly from the oncologist regarding various facets of...
According to findings from a patient-completed questionnaire published in the Journal of Cancer Education, among oncology patients, many favored receiving pertinent information directly from the oncologist regarding various facets of...
According to findings from a...
02/14/2023
Journal of Clinical Pathways
Conference Coverage
Real-World Utilization and Comparative Effectiveness of Treatment Options for Cancer–Associated Venous Thromboembolism
06/04/2022
Janelle Bradley
In the real-world setting, patients with cancer–associated venous thromboembolism remain on anticoagulation for a short period of time and DOACs and warfarin may be associated with better compliance than low molecular weight heparin.
In the real-world setting, patients with cancer–associated venous thromboembolism remain on anticoagulation for a short period of time and DOACs and warfarin may be associated with better compliance than low molecular weight heparin.
In the real-world setting,...
06/04/2022
Journal of Clinical Pathways
News
Immune Checkpoint Inhibitors May Have Been Used Inappropriately in Half of Study Patients with Advanced Cancer Who Were Near the End of Life
05/18/2022
Ellen Kurek
Immune checkpoint inhibitors (ICIs) have been shown to extend progression-free survival and overall survival in patients with a variety of cancers, leading to increases in the systemic treatment of patients with advanced cancer who are near...
Immune checkpoint inhibitors (ICIs) have been shown to extend progression-free survival and overall survival in patients with a variety of cancers, leading to increases in the systemic treatment of patients with advanced cancer who are near...
Immune checkpoint inhibitors...
05/18/2022
Journal of Clinical Pathways
News
Early Palliative Care Reduces End-of-Life Health Care Costs
09/14/2021
Among patients with cancer, receipt of early palliative care reduced the average health system costs in the last month of life, especially through avoided hospitalizations.
Among patients with cancer, receipt of early palliative care reduced the average health system costs in the last month of life, especially through avoided hospitalizations.
Among patients with cancer,...
09/14/2021
Journal of Clinical Pathways
News
Impact of Performance Status on Outcomes Among Patients Receiving ICIs for Advanced Tumors
09/03/2021
Findings from a recent study suggest avoiding the use immune checkpoint inhibitors in patients with advanced malignancy and poor performance status, as the outcomes are poor in this group.
Findings from a recent study suggest avoiding the use immune checkpoint inhibitors in patients with advanced malignancy and poor performance status, as the outcomes are poor in this group.
Findings from a recent study...
09/03/2021
Journal of Clinical Pathways
News
Understanding the Stigmatization of Palliative Care Referral in Oncology
08/24/2021
Findings from a recent study suggest strategies for oncology clinicians to reduce the stigmatizing association of palliative care with end of life.
Findings from a recent study suggest strategies for oncology clinicians to reduce the stigmatizing association of palliative care with end of life.
Findings from a recent study...
08/24/2021
Journal of Clinical Pathways
Conference Coverage
Integrating Palliative Care Into Community Oncology Practice
04/29/2021
04/29/2021
Journal of Clinical Pathways
News
Variation in Treatment Planning of Radiation Therapy Procedures in the United States
02/19/2021
02/19/2021
Journal of Clinical Pathways
News
Episode-Based Payment Model Shortens Radiotherapy Courses But Reduces Reimbursements
11/28/2020
The Radiation Oncology Alternative Payment Model encourages shorter courses of radiotherapy, but emerging technologies with large capital and operating investment needs may see reductions in reimbursements, according to a recent study.
The Radiation Oncology Alternative Payment Model encourages shorter courses of radiotherapy, but emerging technologies with large capital and operating investment needs may see reductions in reimbursements, according to a recent study.
The Radiation Oncology...
11/28/2020
Journal of Clinical Pathways
News
The Impact of Interventions on Serious Illness Conversations
08/14/2026
Rebecca Amrick
Researchers found that intervention strategies focused on clinician reminders could increase rates of serious illness conversations among patients with projected poor health outcomes.
Researchers found that intervention strategies focused on clinician reminders could increase rates of serious illness conversations among patients with projected poor health outcomes.
Researchers found that...
08/14/2026
Journal of Clinical Pathways
News
The Current Treatment Landscape for Myelofibrosis
08/10/2026
Rebecca Amrick
Researchers provided a comprehensive overview of the main treatment options for myelofibrosis (MF), including the primary Janus kinase (JAK) inhibitors, potential combination strategies, and non-pharmacologic interventions used in disease...
Researchers provided a comprehensive overview of the main treatment options for myelofibrosis (MF), including the primary Janus kinase (JAK) inhibitors, potential combination strategies, and non-pharmacologic interventions used in disease...
Researchers provided a...
08/10/2026
Journal of Clinical Pathways
News
Financial Navigation Not Associated With Reduced Financial Hardship
08/03/2026
Rebecca Amrick
A study found no association between financial navigation and improvements in financial hardship or quality of life among patients with cancer, highlighting the need for future research on strategies that could reduce cancer-related financial...
A study found no association between financial navigation and improvements in financial hardship or quality of life among patients with cancer, highlighting the need for future research on strategies that could reduce cancer-related financial...
A study found no association...
08/03/2026
Journal of Clinical Pathways
News
High-Risk Features Impact Patient Survival in Relapsed or Refractory MM
07/27/2026
Rebecca Amrick
A study found that high-risk features such as extramedullary disease, plasma cell leukemia, and focal lesions were associated with poor survival outcomes among patients with relapsed or refractory multiple myeloma (MM).
A study found that high-risk features such as extramedullary disease, plasma cell leukemia, and focal lesions were associated with poor survival outcomes among patients with relapsed or refractory multiple myeloma (MM).
A study found that high-risk...
07/27/2026
Journal of Clinical Pathways
News
Medicare’s Oncology Care Model Demonstrated Modest Payment Reductions for Patients Receiving Chemotherapy
07/24/2026
Rebecca Amrick
A study found that Medicare’s Oncology Care Model resulted in modest payment reductions but had little impact on care utilization or quality for patients undergoing chemotherapy.
A study found that Medicare’s Oncology Care Model resulted in modest payment reductions but had little impact on care utilization or quality for patients undergoing chemotherapy.
A study found that Medicare’s...
07/24/2026
Journal of Clinical Pathways
News
Selinexor Plus Ruxolitinib Demonstrates Improved Efficacy in Patients With Myelofibrosis
07/22/2026
Rebecca Amrick
Selinexor plus ruxolitinib showed improved effectiveness and consistent safety than ruxolitinib alone among patients with myelofibrosis, indicating it could be a promising first-line treatment option.
Selinexor plus ruxolitinib showed improved effectiveness and consistent safety than ruxolitinib alone among patients with myelofibrosis, indicating it could be a promising first-line treatment option.
Selinexor plus ruxolitinib...
07/22/2026
Journal of Clinical Pathways
News
Patients With Functional High-Risk MM Could Benefit from Early Receipt of T-Cell Therapy
07/21/2026
Rebecca Amrick
A study found that defining functional high-risk multiple myeloma (MM) disease progression within 36 months may better identify patients who could benefit from earlier T-cell therapy, potentially improving survival outcomes.
A study found that defining functional high-risk multiple myeloma (MM) disease progression within 36 months may better identify patients who could benefit from earlier T-cell therapy, potentially improving survival outcomes.
A study found that defining...
07/21/2026
Journal of Clinical Pathways
Conference Coverage
Using Real-World Data to Improve HRR Testing Rates Among Patients With mCRPC
07/17/2026
Andy Osterland, PharmD, MS
Andy Osterland, PharmD, MS, discusses real-world patterns of homologous recombination repair (HRR) testing among patients with metastatic castration-resistant prostate cancer (mCRPC), identifying gaps in testing rates and patient access.
Andy Osterland, PharmD, MS, discusses real-world patterns of homologous recombination repair (HRR) testing among patients with metastatic castration-resistant prostate cancer (mCRPC), identifying gaps in testing rates and patient access.
Andy Osterland, PharmD, MS,...
07/17/2026
Journal of Clinical Pathways
News
APP-Led Benign Hematology Consults Improve Access in Community Oncology, Study Finds
07/16/2026
Grace Taylor, MS, MA
A multisite analysis across The US Oncology Network found that Advanced Practice Provider (APP)-led benign hematology consult programs expanded patient access, reduced time to first appointment, and improved operational efficiency in...
A multisite analysis across The US Oncology Network found that Advanced Practice Provider (APP)-led benign hematology consult programs expanded patient access, reduced time to first appointment, and improved operational efficiency in...
A multisite analysis across The...
07/16/2026
Journal of Clinical Pathways
News
Evolutions in Frontline Treatment Patterns for Newly Diagnosed MM
07/15/2026
Rebecca Amrick
Researchers conducted a real-world analysis of treatment patterns for newly diagnosed multiple myeloma (MM) and found that despite increases in triplet and quadruplet regimens, utilization remains suboptimal within community settings.
Researchers conducted a real-world analysis of treatment patterns for newly diagnosed multiple myeloma (MM) and found that despite increases in triplet and quadruplet regimens, utilization remains suboptimal within community settings.
Researchers conducted a...
07/15/2026
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Why is There Variation in Treatment Planning for Medicare Patients?
04/06/2021
04/06/2021
Journal of Clinical Pathways
Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use